Skip to main content
Caplight Logo









CORE Biomedicine

CORE Biomedicine

Private
MassachusettsHealthcare & Life Scienceshttps://corebiomedicine.com/

Last Round

Series A

Jul 28, 2026

Total Funding Raised

$21M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

CORE Biomedicine is a biotechnology company that develops therapeutic approaches for the treatment of luminal cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Application

Keywords

lineage-dependent pathwaysprecision oncologysmall molecule drugsoncology therapeuticsoncology biotechdrug discoveryAI drug discoverytherapy resistancepreclinical biotechlineage addiction oncologyAcute Myeloid LeukemiaAMLurothelial cancerprostate cancergastrointestinal cancersinverse agonist

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CORE Biomedicine Comparables

Compare CORE Biomedicine with similar companies based on industry and business-model similarity.

CORE Biomedicine comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Flare Therapeutics
83%
Antares Therapeutics
76%
HotSpot Therapeutics
73%

CORE Biomedicine Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJul 28, 2026
Series ASep 13, 2025
SeedMar 14, 2025

CORE Biomedicine Investors

Notable investors and investment history

CORE Biomedicine investors
InvestorRounds
YuanBio Venture CapitalSeries A
Mitsubishi UFJ CapitalSeries A
Root Venture PartnersSeries A
Elēkrŏn VenturesSeries A
UTokyo Innovation Platform Co., Ltd.Series A, Seed
Vision Incubate Co., Ltd.Series A, Seed
CD CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 28, 2026

    $21M round led by Elēkrŏn Ventures and UTokyo Innovation Platform.

  • Sep 13, 2025

    Raised Series A with UTokyo Innovation Platform and Vision Incubate.

Recent news

Latest coverage and updates

  • is_developingJul 29, 2026

    CORE Biomedicine, Inc. is planning to develop therapies for a broader set of cancer patients.

  • receives_financingJul 28, 2026

    CORE Biomedicine, Inc. received financing of $21M in Series A on Jul 28th '26.

CORE Biomedicine Filings

Explore SEC and related filing metadata, where available.

CORE Biomedicine filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Firmographic Details

HeadquartersMassachusetts
Year Founded2022
Last FundingJul 28, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?